Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Novavax Inc (NVAX) reports a dramatic revenue increase and strategic collaborations, while navigating regulatory hurdles and ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

Vaccine maker Novavax is seeking to convert the 2022 emergency authorization of its Covid-19 vaccine into full approval. Yet ...

First, to the best of your knowledge, is the post-marketing clinical trial requirement specific to Novavax's BLA filing or do you expect FDA will ask all COVID-19 vaccines, including the mRNA ...

FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDA SHIELD- Utah study ...

Explore Novavax's Q1 2025 earnings insights, highlighting raised revenue forecasts, strategic partnerships, and progress toward non-GAAP profitability ...

(Reuters) - Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S. regulators saying that it sees a pathway to resolving issues with the ...

In the wake of mass restructuring efforts across the Department of Health and Human Services (HHS), the FDA has missed yet another approval decision target date. | GSK had expected to secure an FDA ...